SCHEMBL3844589

SCHEMBL3844589

NC1CCC2CCCC2C1

nearest known ligand 0.39

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18506484 1.00 ALDH1A1 (0.39) ALDH1A1
SCHEMBL16512832 1.00 ALDH1A1 (0.39) ALDH1A1
SCHEMBL9887510 0.94 ALDH1A1 (0.47) ALDH1A1
SCHEMBL1764748 0.94 ALDH1A1 (0.47) ALDH1A1
SCHEMBL9359595 0.94 ALDH1A1 (0.47) ALDH1A1
SCHEMBL12555016 0.94 ALDH1A1 (0.47) ALDH1A1
SCHEMBL9886936 0.94 ALDH1A1 (0.47) ALDH1A1
SCHEMBL24170123 0.92 ALDH1A1 (0.44) ALDH1A1
SCHEMBL12689882 0.92 ALDH1A1 (0.44) ALDH1A1
SCHEMBL12540471 0.92 ALDH1A1 (0.44) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295081-A1 IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY ARCTURUS THERAPEUTICS, INC. 2023-09-21 US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
EP-2096915-A1 METABOLICALLY-STABILIZED INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. Organon (NL) 2009-09-09 EP disclosed
WO-2008063714-A1 METABOLICALLY-STABILIZED INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. ORGANON (NL) 2008-05-29 WO disclosed
US-20080119549-A1 METABOLICALLY-STABILIZED INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. ORGANON (NL) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB ALDH1A1 762/4885
US-20080119549-A1 METABOLICALLY-STABILIZED INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ABHD6 ALDH1A1 346/4885
US-20230295081-A1 IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY NSUN3, POLRMT, NPC1L1 ALDH1A1 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.